Project

Dual targeting of CCr2 and CCR5 as thearpy for hepatocellular carcinoma: can we break immune tolerance?

Code
365N03418
Duration
01 October 2018 → 30 September 2022
Funding
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other basic sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other clinical sciences
    • Other health sciences
    • Nursing
    • Other paramedical sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other translational sciences
    • Other medical and health sciences
Keywords
immune tolerance carcinoma
 
Project description

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide for which, in case of advanced disease, the current standard therapy has limited survival benefit. HCC is an inlammation-related cancer and the link between chronic inflammation and tumour development and progression provides a promising target for the development of new HCC therapy. During advanced HCC, there is a state of unresponsiveness of the immune system against tumour cells/antigens, known as immune to tumour tolerance, which is mediated by specific tumour-assosicated macrophages (TAMs). TAMs procedure cytokines and chemokines that reduce cytotoxic lymphocytes and attract Tregs.